TherapeuticsMD (TXMD) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
TherapeuticsMD Announces Second Quarter 2021 Financial Results
August 4, 2021 6:50 AM EDT- 2Q21 total net product revenue increased by 17% over 1Q21 to $23 million -
- ANNOVERA® prescription growth supported by improved access to providers and increased telemedicine options for patients -
- Prescriptions for IMVEXXY® grew by 8% over 1Q21, outpacing the VVA market -
- Centers for Medicare and Medicaid Services recommended that ANNOVERA receive its own unique national J-Code that could be live as early as Q421 -
- vitaCare signed new customer and pipeline continues to grow... More
